Bank of America Raises Becton, Dickinson and Company (NYSE:BDX) Price Target to $200.00

Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by Bank of America from $185.00 to $200.00 in a report released on Monday,Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. Bank of America‘s target price suggests a potential upside of 6.36% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Royal Bank Of Canada upped their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Barclays increased their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $187.67.

Becton, Dickinson and Company Stock Down 0.8%

Shares of BDX traded down $1.48 during midday trading on Monday, hitting $188.04. The stock had a trading volume of 653,609 shares, compared to its average volume of 2,605,890. The company has a 50 day simple moving average of $166.14 and a two-hundred day simple moving average of $160.20. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The firm has a market cap of $51.81 billion, a price-to-earnings ratio of 56.64, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Insider Activity

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors have recently added to or reduced their stakes in the company. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the third quarter worth about $25,000. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company in the fourth quarter worth $29,000. Meeder Asset Management Inc. increased its holdings in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Finally, Tucker Asset Management LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at about $34,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.